Engineered immune cells take on autoimmune disease
NCT ID NCT06544330
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment for people with severe lupus or scleroderma that hasn't responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty immune cells, and giving them back along with a supporting drug. The main goal is to see if the treatment is safe and tolerable in 48 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A combination of two treatments: SYNCAR-001 (a patient's own immune cells modified to target and destroy faulty immune cells) and STK-009 (a drug that helps those modified cells survive and work longer).
What this could lead to
If it works, this could point toward a new way to control severe autoimmune diseases like lupus and scleroderma without lifelong medication.
What could go wrong
This is a very early (phase 1) and small trial (48 people) focused on safety. The treatment may cause serious side effects, and it is not yet known if it will effectively control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Feinstein Institutes for Medical Research
Manhasset, New York, 11030, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States